SCHEMBL23623644

SCHEMBL23623644

COc1ccc(C(F)(F)F)cc1-c1cc(CNC(=O)c2ccccc2OC(F)(F)F)n[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 1/20 0.45
KCNK9 Q9NPC2 1/20 0.45
TP53 P04637 2/20 0.45
MAPT P10636 2/20 0.45
RXFP1 Q9HBX9 4/20 0.44
NCS1 P62166 1/20 0.44
SCN8A Q9UQD0 2/20 0.42
SCN10A Q9Y5Y9 2/20 0.42
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
HCN1 O60741 1/20 0.41
HPGD P15428 3/20 0.41
GLA P06280 1/20 0.41
ALDH1A1 P00352 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
PPARA Q07869 1/20 0.41
CSNK1D P48730 1/20 0.41
CSNK1E P49674 1/20 0.41
POLB P06746 1/20 0.41
SORT1 Q99523 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23623254 0.91 KCNK3 (0.47) KCNK3KCNK9TP53MAPTROCK2
SCHEMBL23623811 0.91 KCNK3 (0.50) KCNK3KCNK9TP53MAPTROCK2
SCHEMBL23611752 0.90 CLK1 (0.48) KCNK3KCNK9TP53MAPTRXFP1
SCHEMBL23623295 0.90 KCNK3 (0.48) KCNK3KCNK9TP53MAPTROCK2
SCHEMBL23623251 0.89 ALDH1A1 (0.46) KCNK3KCNK9TP53MAPTROCK2
SCHEMBL24177603 0.88 KCNK3 (0.44) KCNK3KCNK9TP53MAPTROCK2
SCHEMBL23623839 0.85 POLB (0.47) KCNK3KCNK9TP53MAPTROCK2
SCHEMBL23623255 0.85 KCNK3 (0.49) KCNK3KCNK9TP53MAPTROCK2
SCHEMBL23623235 0.84 HPGD (0.49) KCNK3KCNK9TP53MAPTROCK2
SCHEMBL23623559 0.84 POLB (0.47) KCNK3KCNK9TP53ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091590-A1 COMPOUNDS FOR USE IN TREATING GASTRIC CANCER BERG LLC (US) 2023-05-25 WO disclosed
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2022-01-06 US disclosed
US-11091447-B2 UBE2K modulators and methods for their use BERG LLC (US) 2021-08-17 US disclosed
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE THLIVERIS, ANDREW T. 2021-07-15 US disclosed
WO-2021138540-A1 POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER BERG LLC (US) 2021-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091447-B2 UBE2K modulators and methods for their use UBE2N, UBE2B, UBE2E1 KCNK3 2414/4885KCNK9 2438/4885TP53 896/4885
US-20220002255-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 KCNK3 2414/4885KCNK9 2438/4885TP53 896/4885
US-20210214320-A1 UBE2K MODULATORS AND METHODS FOR THEIR USE UBE2N, UBE2B, UBE2E1 KCNK3 2414/4885KCNK9 2438/4885TP53 896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.